RecruitingPhase 1NCT03922555

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Phase I Trial of ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Sponsor

Massachusetts General Hospital

Enrollment

18 participants

Start Date

Jul 12, 2019

Study Type

INTERVENTIONAL

Conditions

Neurological Cancer

Summary

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ASTX727 for people with neurological cancer. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGASTX727

ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.

Locations(3)

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03922555

Related Trials

Wearable Devices and Biomarkers Project (Healthiomics)

NCT051067251 location

Standard Follow-up Program Neuro-oncology Patients (SFP Neuro-Oncology)

NCT065289121 location